UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015565
Receipt number R000018086
Scientific Title Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer
Date of disclosure of the study information 2014/10/30
Last modified on 2014/10/30 12:32:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer

Acronym

Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer

Scientific Title

Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer

Scientific Title:Acronym

Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer

Region

Japan


Condition

Condition

Refractory small-cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy and safety of nab-paclitaxel in combination with carboplatin in refractory small-cell lung cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Response rate (RR)

Key secondary outcomes

Disease control rate (DCR), Progression free survival (PFS), Overall survival (OS), and Safety


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Nab-paclitaxel at the dose of 100mg/m2 (day 1, 8, 15) and carboplatin at the dose of area under curve 5 (day 1) are administered every 3 weeks. Treatment can be continued unless PD or toxicity that is not tolerable is found.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1) Patients with histlogically or cytologically confirmed small cell lung cancer
2) Patients are difficult to treat with adapted drugs to the small cell lung cancer. (patients completed or not acceptable the standard chemotherapy)
3) 20<=, <75 years old
4) Without active cancer other than NSCLC
5) At least one measurable lesion
6) With adequate organ function
neutrophil count => 1,500/mm^3
platelet => 100,000/mm^3
hemoglobin => 9.0g/dL
AST/ALT < 2.5 times less than ULN
T.Bil <= 1.5mg/dL
serum creatinine <= 1.5mg/dL
ECG: without clinically problematic abnormalities
Peripheral neuropathy <= Grade 1
7) Life expectancy of at least 3 months
8) ECOG performance status 0 or 2
9) With written informed consent

Key exclusion criteria

1) Symptomatic brain metastasis
2) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy
3) With active double cancer or multicentric cancer
4) Treated with radiotherapy within the past four weeks.
5) With clinically important complications.
6) With pleural effusion or pericardial effusion accumulates which need drainage
7) With the history of hypersensitivity for nab-paclitaxel, CBDCA
8) Main organs had a serious medical risk factor, and the physicians judged treatment not to be safe.
9) Physician concludes that the patient's participation in this trial is inappropriate

Target sample size

22


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshiki Ishii

Organization

Dokkyo Medical University

Division name

Department of Pulmonary Medicine and Clinical Immunology

Zip code


Address

880 Kitakobayashi, Mibu, Tochigi, Japan

TEL

0282-87-2151

Email

ishiiysk@dokkyomed.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ryo Arai

Organization

Dokkyo Medical University

Division name

Department of Pulmonary Medicine and Clinical Immunology

Zip code


Address

880 Kitakobayashi, Mibu, Tochigi, Japan

TEL

0282-87-2151

Homepage URL


Email

r-arai@dokkyomed.ac.jp


Sponsor or person

Institute

Dokkyo Medical University

Institute

Department

Personal name



Funding Source

Organization

Dokkyo Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Tochigi-kitakan Thoracic Oncology Research Organization (TOTORO)

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 10 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 09 Month 03 Day

Date of IRB


Anticipated trial start date

2014 Year 10 Month 30 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 10 Month 30 Day

Last modified on

2014 Year 10 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018086


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name